Failure To Launch: The Patent Thicket Delay Of US Biosimilars
Biologics originators successfully argued that they required longer exclusivity periods without competition from follow-on products because patents covering the originators' products would not pose the same barriers to entry that patents...To view the full article, register now.
Already a subscriber? Click here to view full article